Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
Recent Articles
RELATED ARTICLES
-
Stealthy eLong Power sneaks closer to U.S. listing
- China-U.S. IPOs take big step toward resumption with Cheche listing
-
Geely flexes deal-making muscle as Lotus Technology nears listing finish line
LOT.US
-
ZG Group and Aquila aim to score Hong Kong’s first SPAC merger success
7836.HK
-
Hong Kong’s first SPAC pumps up with steel trader ZG Group
7836.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
